A formulary change for BCBSRI Commercial plans is being made in response to the current growth hormone shortage. 

Several plans currently cover Norditropin and Genotropin as a preferred brand growth hormone. As of 1 de dezembrost, 2023, Omnitrope was added to coverage as an additional preferred brand growth hormone option. Norditropin and Genotropin remain covered as a preferred brands. Manufacturers estimate that growth hormone shortages will continue through 2023.

If your patients have any questions about this change, here are some resources you can offer them to call the number on their member ID card